The Mectizan (Ivermectin) Donation Program for Riverblindness as a Paradigm for Pharmaceutical Industry Donation Programs
(2002; 32 pages)


The debate over pharmaceutical pricing policies and access to AIDS-related drug treatment has greatly intensified over the past year. In this context, along with a succession of price reductions, several research-based pharmaceutical manufacturers have instituted donation programs as a response to the need for improved access to these drugs by HIV-infected persons in the developing world. The purpose of this paper is to examine Merck's Mectizan (ivermectin) donation as a successful paradigm for pharmaceutical industry donation programs: what characterizes it, what it responds to, how it was instituted, who implements it, who benefits, and how to measure its impact.

The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: December 6, 2017